Gynaecological cancer
Explore our latest news, features and educational resources in this specialist area.
SMC accepts niraparib for some gynecological cancers
Research showed that niraparib significantly improved progression-free survival compared with placebo.
Ovarian cancer treatment recommended via Cancer Drugs Fund
NICE draft guidance recommends olaparib in combination with bevacizumab for some people with advanced, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer.
Niraparib (Zejula▼): reports of severe hypertension and posterior reversible encephalopathy syndrome (PRES), particularly in early treatment
Monitor blood pressure at least weekly for 2 months from initiation and then monthly afterwards for the first year and periodically thereafter during treatment
